Last reviewed · How we verify
NCT04935814: CORVaso
Cardiac Output Response to Vasopressin Infusion In Abdominal Surgery Patients Under Mechanical Ventilation
Phase 4 trial testing Vasopressin, Arginine in Major Abdominal Surgery in 20 participants. Completed in 2 August 2022.
2 August 2022
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 20 |
| Start date | 9 June 2021 |
| Primary completion | 2 August 2022 |
| Estimated completion | 2 August 2022 |
| Sites | 1 location across France |
Drugs / interventions tested
- Vasopressin, Arginine — full drug profile →
Conditions studied
- Major Abdominal Surgery — all drugs for Major Abdominal Surgery →
- General Anesthesia — all drugs for General Anesthesia →
- Mechanical Ventilation — all drugs for Mechanical Ventilation →
- Vasopressin Infusion — all drugs for Vasopressin Infusion →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
18 and older, any sex, with Major Abdominal Surgery or General Anesthesia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators propose to explore the hemodynamic variations induced by vasopressin and its influence on cardiac output, mean systemic pressure, and venous return resistance measured through cardiopulmonary interactions, according to the approach proposed by Guyton, in patients undergoing major abdominal surgeries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04935814
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Vasopressin, Arginine
Trials testing the same drug.
- NCT03640949 — Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest · Phase 2, PHASE3 · completed
- NCT03088345 — Early Use of Vasopressin in Post-Fontan Management · Phase 2, PHASE3 · completed
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04935814 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 5 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04935814.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing